Loredana Puca

List of Publications by Year
in descending order

26 papers	3,755 citations	394421 19 h-index	642732 23 g-index
28 all docs	28 docs citations	28 times ranked	6208 citing authors

#	Article	IF	Citations
1	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced Materials, 2022, 34, e2100096.	21.0	24
2	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022). Advanced Materials, 2022, 34, .	21.0	0
3	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	12.6	75
4	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377.	12.8	16
5	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	12.8	76
6	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1157-1164.	4.1	44
7	Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030593.	6.2	76
8	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
9	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	12.8	143
10	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	105
11	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	7.0	177
12	N-Mycâ€“mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. Journal of Clinical Investigation, 2019, 129, 3924-3940.	8.2	115
13	First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer.. Journal of Clinical Oncology, 2019, 37, 260-260.	1.6	3
14	SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).. Journal of Clinical Oncology, 2019, 37, 5065-5065.	1.6	0
15	Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404.	12.8	246
16	Emerging Variants of Castration-Resistant Prostate Cancer. Current Oncology Reports, 2017, 19, 32.	4.0	150
17	Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discovery, 2017, 7, 462-477.	9.4	735
18	Abstract 992: Patient-derived tumor organoids of neuroendocrine prostate cancer. , 2017, , .		1

#	Article	IF	Citations
19	Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC).. Journal of Clinical Oncology, 2017, 35, 5029-5029.	1.6	5
20	An emerging role for cytopathology in precision oncology. Cancer Cytopathology, 2016, 124, 167-173.	2.4	23
21	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577.	16.8	394
22	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	30.7	1,193
23	Defining a molecular subclass of treatment resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5004-5004.	1.6	3
24	Î±-Arrestins â€“ new players in Notch and GPCR signaling pathways in mammals. Journal of Cell Science, 2014, 127, 1359-1367.	2.0	50
25	Î±-arrestin 1 (ARRDC1) and Î²-arrestins cooperate to mediate Notch degradation in mammals. Journal of Cell Science, 2013, 126, 4457-4468.	2.0	52
26	Akt Regulates Drug-Induced Cell Death through Bcl-w Downregulation. PLoS ONE, 2008, 3, e4070.	2.5	20